Journal

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease

Read time: 1 mins

Published:1st Dec 2018

Author: Dal Molin GZ, Westin SN, Coleman RL.

Source: Future Oncology

Availability: Pay for access, or by subscription

Ref.:Future Oncol. 2018;14(30):3101-3110.

DOI:10.2217/fon-2018-0215

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease

Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as treatment in patients with recurrent high-grade ovarian carcinoma and resulting in approval of rucaparib for patients with both germline and somatic BRCA mutation. Data from the Phase III trial ARIEL3 led to approval in platinum-sensitive disease as maintenance. This article reviews the efficacy, safety, pharmacokinetics and pharmacodynamics of rucaparib as well as future and ongoing trials.

Read abstract on library site Access full article